Intech Investment Management LLC Sells 325 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Intech Investment Management LLC trimmed its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 11.0% during the first quarter, Holdings Channel.com reports. The fund owned 2,632 shares of the medical research company’s stock after selling 325 shares during the quarter. Intech Investment Management LLC’s holdings in Thermo Fisher Scientific were worth $1,530,000 as of its most recent filing with the SEC.

A number of other hedge funds have also bought and sold shares of the business. Capital Research Global Investors increased its position in Thermo Fisher Scientific by 6.9% during the fourth quarter. Capital Research Global Investors now owns 7,989,614 shares of the medical research company’s stock worth $4,240,824,000 after acquiring an additional 517,137 shares during the period. Norges Bank bought a new position in Thermo Fisher Scientific during the fourth quarter worth about $2,909,524,000. Franklin Resources Inc. increased its position in Thermo Fisher Scientific by 16.0% during the fourth quarter. Franklin Resources Inc. now owns 2,518,760 shares of the medical research company’s stock worth $1,336,933,000 after acquiring an additional 347,560 shares during the period. The Manufacturers Life Insurance Company increased its position in Thermo Fisher Scientific by 3.0% during the fourth quarter. The Manufacturers Life Insurance Company now owns 2,349,580 shares of the medical research company’s stock worth $1,247,134,000 after acquiring an additional 69,132 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its position in Thermo Fisher Scientific by 4.2% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 2,277,266 shares of the medical research company’s stock worth $1,208,750,000 after acquiring an additional 92,338 shares during the period. 89.23% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities analysts have commented on the stock. Barclays decreased their target price on shares of Thermo Fisher Scientific from $615.00 to $600.00 and set an “equal weight” rating on the stock in a report on Friday, June 28th. JPMorgan Chase & Co. raised their target price on shares of Thermo Fisher Scientific from $600.00 to $650.00 and gave the company an “overweight” rating in a report on Thursday, April 25th. HSBC raised their target price on shares of Thermo Fisher Scientific from $660.00 to $670.00 and gave the company a “buy” rating in a report on Tuesday, April 30th. Evercore ISI decreased their target price on shares of Thermo Fisher Scientific from $615.00 to $600.00 and set an “outperform” rating on the stock in a report on Tuesday, July 2nd. Finally, Jefferies Financial Group reissued a “buy” rating and issued a $650.00 target price (up from $600.00) on shares of Thermo Fisher Scientific in a report on Monday, June 3rd. Five analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and a consensus target price of $605.63.

Thermo Fisher Scientific Trading Down 1.2 %

NYSE:TMO traded down $6.27 during mid-day trading on Friday, hitting $534.35. 1,667,269 shares of the company’s stock were exchanged, compared to its average volume of 1,636,182. The company has a 50 day simple moving average of $565.05 and a 200-day simple moving average of $564.45. The company has a current ratio of 1.70, a quick ratio of 1.33 and a debt-to-equity ratio of 0.68. Thermo Fisher Scientific Inc. has a fifty-two week low of $415.60 and a fifty-two week high of $603.82. The firm has a market capitalization of $203.97 billion, a P/E ratio of 34.28, a PEG ratio of 2.49 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, April 24th. The medical research company reported $5.11 EPS for the quarter, topping the consensus estimate of $4.70 by $0.41. The business had revenue of $10.35 billion for the quarter, compared to the consensus estimate of $10.14 billion. Thermo Fisher Scientific had a net margin of 14.20% and a return on equity of 18.45%. As a group, research analysts expect that Thermo Fisher Scientific Inc. will post 21.64 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, October 15th. Stockholders of record on Friday, September 13th will be given a $0.39 dividend. The ex-dividend date of this dividend is Friday, September 13th. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.29%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.01%.

Insider Transactions at Thermo Fisher Scientific

In other news, SVP Michael A. Boxer sold 2,000 shares of the business’s stock in a transaction that occurred on Friday, April 26th. The shares were sold at an average price of $567.94, for a total value of $1,135,880.00. Following the transaction, the senior vice president now owns 13,083 shares in the company, valued at approximately $7,430,359.02. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $567.28, for a total value of $5,672,800.00. Following the completion of the sale, the chief executive officer now owns 123,816 shares in the company, valued at approximately $70,238,340.48. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Michael A. Boxer sold 2,000 shares of Thermo Fisher Scientific stock in a transaction on Friday, April 26th. The shares were sold at an average price of $567.94, for a total transaction of $1,135,880.00. Following the completion of the sale, the senior vice president now owns 13,083 shares of the company’s stock, valued at approximately $7,430,359.02. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 22,000 shares of company stock worth $12,532,780. Company insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.